IRCT20200623047902N37招募中Unknown
Bioequivalence study of Dapagliflozin 10 mg manufactured by Actover Co. versus originator brand in healthy volunteers in fasting condition
Actover Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Dapagliflozin
研究者
相似试验
招募中
Unknown
Bioequivalence study of dapagliflozin 10 mg tabletIRCT20230222057495N18Viana Darou Sanat Pharmaceutical company24
招募中
Unknown
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
已完成
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 25 mg Combined Tablet formulations.IRCT20180620040164N57Darou darman Pars Co.24
已完成
不适用
Bioequivalence Study of Dapagliflozin 10 mg Film-coated TabletsHealthyNCT06127212Dexa Medica Group24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26